Toronto · Independent Shariah screening · Screened October 1, 2026

Screened October 1, 2026 · TSX: BCT (also NASDAQ: BCTX) · Q3 FY2026 (nine months ended April 30, 2026; unaudited, filed June 2026) + market data September 2026

Debt ÷ market cap 0% / 33%
Non-compliant income 100% / 5%

BriaCell Therapeutics Corp.

BCT · TSX · Healthcare

FAIL

Is BriaCell Therapeutics (BCT) halal?

BriaCell Therapeutics (TSX: BCT), the immuno-oncology biotech advancing Bria-IMT through a pivotal Phase 3 trial in metastatic breast cancer, gets a FAIL: it is pre-revenue with nil sales, so its separately disclosed financial income of C$430,205 (nine months ended April 30, 2026) is effectively 100% of income - far above the ~5% non-compliant income ceiling. Debt is zero and the business gate passes.

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The two-gate Shariah screen

Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).

Gate one: the business — PASSED

BriaCell Therapeutics Corp. (TSX: BCT; NASDAQ: BCTX) is a clinical-stage biotechnology company headquartered in West Vancouver, focused on developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy in a pivotal Phase 3 trial for metastatic breast cancer; it also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer, and a soluble CD80 protein therapeutic licensed from the University of Maryland, Baltimore County. No non-permissible segments are disclosed anywhere in the filings reviewed - no alcohol, cannabis, gambling, conventional banking or insurance, weapons, pork, tobacco, or adult-entertainment activities. Developing cancer immunotherapies is not a flagged activity under standard AAOIFI-style screens. The business gate passes. Facts only, no fatwa.

Gate two: the ratios — FAILED

The non-compliant income gate fails. The Q3 FY2026 statements (nine months ended April 30, 2026) disclose a separate "Financial income, net" line: C$430,205 for the nine-month period, up from C$69,310 a year earlier - the company's FY2025 10-K describes this line as driven mainly by interest income on cash balances. The company reports nil revenue - it is pre-revenue, with no approved product - so this financial income is effectively the company's only income, i.e. interest-type income is about 100% of income, far above the ~5% ceiling. The income is earned on the company's cash pile: cash and marketable securities of about C$22.80M at April 30, 2026, strengthened by ~C$27.9M in net equity financing proceeds during the period. The debt gate passes with room to spare: total debt of C$0.00 at April 30, 2026 - liabilities are only trade payables and accruals of about C$3.7M - a debt-to-market-cap ratio of about 0% against a market capitalization of about C$49.85M (September 2026; ~8.70M shares outstanding). All figures recomputed from the cited sources; BriaCell reports in Canadian dollars.

What other screeners say

No public Zoya, Musaffa or ShariaPortfolio coverage was found for BriaCell Therapeutics (BCT/BCTX) as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.

The bottom line

BriaCell Therapeutics (BCT) is a FAIL under this site's AAOIFI-style screening: the non-compliant income gate fails because the pre-revenue biotech's separately disclosed financial income - C$430,205 in the nine months ended April 30, 2026 (mainly interest on cash balances) - is effectively 100% of income with nil revenue, far above the ~5% ceiling, earned on its ~C$22.80M cash and marketable securities pile. The debt gate passes: zero debt is about 0% of a ~C$49.85M market cap. The business gate passes: Bria-IMT is a cell-based immunotherapy in pivotal Phase 3 for metastatic breast cancer, alongside Bria-OTS and soluble CD80 programs - no haram segments are disclosed. No public Zoya, Musaffa or ShariaPortfolio rating was found for this ticker as of October 2026. As with every screener here, this is a rules-based screening of published figures, not a religious ruling - consult a qualified scholar for personal guidance.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Halal alternatives in this sector

BCT did not pass the screen. These companies in the same sector passed:

Sources

Frequently asked questions

Is BriaCell Therapeutics stock halal?

Based on this screener's AAOIFI-style checks, BriaCell fails: the pre-revenue immuno-oncology biotech's separately disclosed financial income - C$430,205 in the nine months ended April 30, 2026 - is effectively 100% of its income with nil revenue, far above the ~5% non-compliant income ceiling. Debt is zero and the business gate passes, but the income gate fails. This is a screening result, not investment advice or a religious ruling.

How does BriaCell Therapeutics score on the debt ratio?

The debt gate passes with room to spare: the company carries zero debt (C$0.00 total debt at April 30, 2026), with total liabilities of only about C$3.7M in trade payables and accruals. Against a market capitalization of about C$49.85M (September 2026), the debt-to-market-cap ratio is about 0%.

Why does a pre-revenue biotech fail the income gate?

BriaCell reports no revenue at all - it is pre-revenue, developing cancer immunotherapies (Bria-IMT pivotal Phase 3 in metastatic breast cancer, Bria-OTS, soluble CD80). Its separately disclosed financial-income line (C$430,205 for the nine months ended April 30, 2026, vs C$69,310 a year earlier - largely interest on cash balances) is therefore the company's only income. Interest-type income is effectively 100% of income, far above the ~5% ceiling, so the non-compliant income gate fails. The company holds about C$22.80M in cash and marketable securities, and that cash pile is what generates the income.

Does BriaCell Therapeutics have any haram business segments?

No: BriaCell is a clinical-stage biotechnology company developing targeted immunotherapies for cancer - Bria-IMT (cell-based immunotherapy in pivotal Phase 3 for metastatic breast cancer), Bria-OTS (personalized off-the-shelf immunotherapy for breast and prostate cancer), and a soluble CD80 protein therapeutic licensed from the University of Maryland. No alcohol, cannabis, gambling, conventional banking or insurance, weapons, pork, tobacco, or adult-entertainment activities are disclosed, so the business gate passes.

Do Zoya, Musaffa, or ShariaPortfolio rate BriaCell Therapeutics?

No public coverage was found as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.